Navigation Links
Research on improvements in diagnosing and treating tuberculosis
Date:6/19/2012

y. Among infectious diseases, this is the main cause of death among young adults in developing countries, particularly among the poorest ones. It is estimated that there are five million new cases every year throughout the world and that the possibility of being cured is only 60%. The efficacy of programs to fight tuberculosis continues to be burdened by the need to keep patients in treatment for 6 to 24 months. Financing and support for trials are limited.

With its participation in this project, UC3M has joined large-scale research in the area of health science. The project, which began in May of this year and is expected to last for sixty months, is being led by the pharmaceutical company GlaxoSmithKline and includes 21 prestigious international partners. The partners who come from private industry are: GlaxoSmithKline, Sanofi-Aventis, Janssen, Microsense Medtech and ZF Screens. Partners from the academic world are: the University of Liverpool, UC3M, Max Plank Institute, Erasmus University, Health Protection Agency UK, Institut Pasteur, St Georges University London, University of St Andrews, EPFL, Univ. of Leicester, University College of London, VU University, the Liverpool School of Tropical Medicine and Uppsala University.


'/>"/>
Contact: Ana Herrera
oic@uc3m.es
Carlos III University of Madrid
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Grant program to spur new research on Alzheimers disease by encouraging collaboration
2. Research breakthrough: High brain integration underlies winning performances
3. IOC recognizes University of Calgary Sports Injury Research Prevention Centre
4. Scripps Research Institute announces five-year research collaboration with Bristol-Myers Squibb
5. Researchers identify need to sample multiple tumor zones in breast cancer
6. London researchers discover novel mechanism involved in key immune response
7. NTU researchers study little mighty creature for scientific breakthrough
8. FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisory Board
9. UTMB researchers create powerful new method to analyze genetic data
10. Astellas and DNDi to collaborate on new drug discovery research for the treatment of NTDs
11. FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisor Board
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Research on improvements in diagnosing and treating tuberculosis
(Date:12/17/2014)... 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... technology than the iPhone 5S, Samsung introduces for ... product. The Galaxy S5 home button ...
(Date:12/17/2014)... 2014  HITLAB SM announced today its ... to confirm its adherence to current U.S. Food ... HITLAB to conduct regulated smart device and smart ... patient safety and research quality. "HITLAB ... and delivery with innovative technology," said Laura ...
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this ... in biomedical applications. Chemical sensors help in recording ... during surgical procedures. The Global Chemical Sensor market ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... drugs currently studied in clinical trials appears to reduce ... at Georgetown University Medical Center report in an upcoming ... They say the results suggest that this class of ... been able to do-- prevent the long-term and continuing ...
... the specific biological mechanisms believed to lead to ... Diamond Blackfan anemia (DBA). Scientists say with further ... to current thinking about treatment for this disease ... George Thomas, PhD, Stefano Fumagalli, PhD, ...
... or ,gloopiness, of different parts of cancer cells increases ... according to new images that provide fundamental insights into ... today (15 March). The ... cells whilst they are dying as a result of ...
Cached Biology News:Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 2Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 3Cellular discovery may lead to targeted treatment for rare form of anemia 2Cellular discovery may lead to targeted treatment for rare form of anemia 3A sticky business -- how cancer cells become more 'gloopy' as they die 2
(Date:12/24/2014)... DALLAS and NEW YORK ... (NASDAQ: PTBI, PTBIW), a biopharmaceutical company advancing patient care ... public offering of 3,500,000 shares of common stock, and ... of common stock, at an offering price of $4.00 ... a per share exercise price of $5.00, are exercisable ...
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... precision thermal shipping products for cells and ... will hold its 2015 Annual Meeting of Stockholders on ... the expected date for the Annual Meeting represents a ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn ... biotechnology company, Syngenta, are in the process of being ... The consolidated case is In Re: Syngenta AG MIR ... District Court for the District of Kansas. , Management ... been handed over to U.S. District Judge John W. ...
(Date:12/24/2014)... 23, 2014 SoundConnect’s ... designed to introduce cutting edge communication technology, ... partners of platform upgrades. This webinar series ... users in their quest to leverage web ... According to SoundConnect’s Marketing Manager, Seanna Baumgartner, ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... , , , , , , ... Synthesis with the new Transcriptor Reverse, Transcriptase , ... With the new recombinant ,Transcriptor Reverse Transcriptase, you will , , , ... cDNA transcripts , Reverse transcribe difficult templates with high secondary structure , ...
... , , , , , ... , , Co-transfections , ... DNA constructs work in your cell line. Also, determine the ratio of DNA ,to FuGENE ... ,provides good expression levels. Then, perform the transfection, ensuring the ,DNA / FuGENE 6 Reagent ...
... , , , , ... FuGENE 6 Transfection Reagent in Vector-based shRNA Experiments , ... RNA interference induced by siRNAs or shRNAs allows reliable down-regulation of ... into cells are used directly for transient gene silencing, ,vectors that encode for the ...
Cached Biology Technology:Transcriptor Reverse Transcriptase 2Transcriptor Reverse Transcriptase 3Transcriptor Reverse Transcriptase 4Transcriptor Reverse Transcriptase 5Uses and Applications of FuGENE 6 Transfection Reagent 2
Rad 51C Immunogen: His-tagged human Rad 51C, over-expressed in E. coli Storage: 4 C...
...
...
... recognizes 30% of IgM-rheumatoid factor ... does not cross-react with IgM, IgA, ... nor with pooled F(Ab)2 fragments. This ... to detect rheumatoid factor. Product Category: ...
Biology Products: